ImmunityBio vs Moderna: Biotech Firms Face Off for Investment Potential

ImmunityBio (IBRX) and Moderna (MRNA) are biotech firms relying on single key drugs and pipeline expansion for growth. IBRX has marketed drug Anktiva for bladder cancer, with sales up 700% YoY. However, regulatory scrutiny and a sole dependence on Anktiva pose concerns. Moderna focuses on mRNA-based therapies for multiple indications, including respiratory diseases and cancer. Both companies have potential for future growth, but IBRX's dependence on Anktiva increases execution risk.